Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC

Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0127523. doi: 10.1128/aac.01275-23. Epub 2024 Mar 12.

Abstract

Multidrug-resistant tuberculosis (MDR-TB) patients not cured at the time of stopping treatment are exposed to Minimum Inhibitory Concentration (MIC) and sub-MIC levels for many months after discontinuing bedaquiline (BDQ) or clofazimine (CFZ) treatment. In vitro cultures treated with BDQ and CFZ sub-MIC concentrations clearly showed enrichment in the Rv0678 mutant population, demonstrating that pre-existing Rv0678 mutants can be selected by sub-MIC concentrations of BDQ and CFZ if not protected by an alternative MDR-TB treatment.

Keywords: Rv0678; bedaquiline; clofazimine; drug resistance; tuberculosis.

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Clofazimine / pharmacology
  • Diarylquinolines / pharmacology
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis* / genetics
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / microbiology

Substances

  • Clofazimine
  • bedaquiline
  • Antitubercular Agents
  • Diarylquinolines